Abbott (NYSE:ABT) has lost a bid to dismiss a lawsuit by former investors in Tendyne Holdings, who claim that the healthcare giant dragged its heels on obtaining a regulatory approval that would have triggered a $50 million milestone payment. Abbott in September 2015 paid $225 million up front for the stake it didn’t already own in […]
Abbott (NYSE:ABT) said today it launched a US-based pivotal clinical study of its Tendyne transcatheter mitral valve replacement system designed to treat mitral regurgitation. In the trial, the Abbott Park, Ill.-based company will explore the safety and efficacy of the system in treating patients with mitral regurgitation. Abbot touted the Tendyne as the first and only mitral […]
Investors in Tendyne Holdings yesterday sued Abbott (NYSE:ABT) over a $50 million milestone payment, alleging that the healthcare giant dragged its heels on obtaining a regulatory approval that would have triggered a $50 million milestone payment. Abbott in September 2015 paid $225 million up front for the stake it didn’t already own in Roseville, Minn.-based Tendyne, which was developing a transcatheter […]
Abbott (NYSE:ABT) said today that it closed the $250 million acquisition of replacement mitral valve maker Tendyne Holdings. Abbott said in July that it put another $225 million on top of the stake it already owned in Roseville, Minn.-based Tendyne, which raised a $25 million Series C round in April 2014. The total value of the Tendyne deal […]
CEO Miles White proved today that he wasn’t just blowing smoke last week when he said that Abbott (NYSE:ABT) has powder to burn and is ready to use it. Abbott today revealed a pair of investments aimed at building out its presence in the mitral valve replacement market, saying it put another $225 million on top of the […]
Tendyne Holdings this month said its transcatheter mitral valve implant was implanted in the 1st U.S. patient as part of a global feasibility study.
Medtech startup Tendyne Holdings landed $25 million in Series C funding, planning on using the new cash for further research & development of its transcatheter mitral valve technology.
The 4-year-old company’s device provides minimally invasive treatment of mitral regurgitation. Tendyne is working on engineering an implantation system that would allow physicians to re-position or retrieve the valve even after full deployment.